SCHEMBL26530187

SCHEMBL26530187

Cc1cncc(Cn2nc(-c3ccc(OC(C)F)nc3)ccc2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GRIN1 Q05586 5/20 0.45
▸ GRIN2B Q13224 5/20 0.45
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ MET P08581 5/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ NEK2 P51955 1/20 0.42
▸ LIMK1 P53667 1/20 0.42
▸ TYRO3 Q06418 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ TP53 P04637 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PDE4A P27815 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4C Q08493 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26527929 0.90 GRIN2B (0.44) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL26527935 0.90 PDE4A (0.41) MEN1KMT2AMETCHEK1NEK2
SCHEMBL26527912 0.85 MET (0.46) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL26530948 0.82 CHEK1 (0.44) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL27066290 0.82 MEN1 (0.47) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL23528379 0.82 GRIN2B (0.50) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL29569798 0.82 GRIN2B (0.50) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL26530988 0.81 CHEK1 (0.43) GRIN1GRIN2BMEN1KMT2AMET
SCHEMBL23558969 0.81 GRIN2B (0.51) GRIN1GRIN2BMEN1KMT2ATP53
SCHEMBL26531603 0.81 MEN1 (0.48) GRIN1GRIN2BMEN1KMT2AMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 GRIN1 728/4885GRIN2B 1553/4885MEN1 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback